With competitors circling, ViiV wins another label update for long-acting HIV injectable Cabenuva

Just over a year after it was initially approved, GSK’s HIV unit ViiV Healthcare has found yet another way to make Cabenuva’s label even more attractive.

Cabenuva consists of two extended-release injectables: cabotegravir, which is developed by ViiV, and rilpivirine from J&J’s Janssen which is also marketed individually under the brand names Edurant and Rekambys. Previously, patients starting out on the long-acting HIV treatment were required to first take cabotegravir and rilpivirine by mouth for one month to assess their tolerability of the medicines before moving on to injections.